Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2007-03-19 Regulatory Filings
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
Announcement
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to Rule 13.09 of the Listing Rules on The Stock Exchange of Hong Kong Limited. It informs about the company's permission from the State Food and Drug Administration of the PRC to conduct Phase II clinical trials for a drug. The document is short (2751 characters) and does not contain financial statements or detailed financial data. It is an update on regulatory approval and clinical trial progress, not a financial report or detailed management discussion. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories like Annual Report, Earnings Release, or Management Reports.
2007-03-19 English
Results of General Meetings
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the results of an Extraordinary General Meeting (EGM) held on 1 February 2007. It details the voting outcomes on resolutions related to the refreshment of the General Mandate. The text includes vote counts, percentages, and mentions the scrutineer. There is no detailed financial data or comprehensive report content, only the official voting results. The document length is 4047 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2007-02-02 English
Announcement
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management executive, specifically the CEO, Dr. Samuel K Zia. It references compliance with Rule 13.09 of the Listing Rules, which typically governs disclosure of changes in directors or senior management. The content focuses solely on the appointment and background of the new CEO without any financial data, report attachments, or other types of filings. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is clearly an announcement, not a full report or transcript.
2007-01-29 English
Circular (Refreshment of general mandate to allot and issue shares)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from the board of Uni-Bio Science Group Limited regarding the "Refreshment of General Mandate to Allot and Issue Shares." It includes detailed information about the existing general mandate, usage since the last AGM, proposed new mandate, letters from the Independent Board Committee and Independent Financial Adviser, and a notice of an Extraordinary General Meeting (EGM) to approve the refreshment of the mandate. The document is not a full financial report but rather a detailed shareholder communication related to capital issuance authority and an upcoming shareholder meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2007-01-16 English
Proxy Form
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for use by shareholders at an extraordinary general meeting (EGM) of Uni-Bio Science Group Limited. It includes instructions for appointing a proxy to vote on resolutions related to share allotment mandates. The content is procedural and related to voting arrangements rather than the results of the vote or the meeting itself. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI), as it is sent to shareholders to provide information and request votes for the meeting.
2007-01-16 English
Announcement
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change of company secretary and qualified accountant, detailing the resignation of one individual and the appointment of another. It does not contain financial statements, audit results, or detailed management discussion. It is a corporate governance-related announcement about board-level personnel changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming this classification.
2007-01-16 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.